Wilmington, DE – FyMed is advancing targeted candidates for both early and advanced colorectal cancer. FY405B is an investigational cancer targeted cytotoxic therapy, a new class of treatments that use the body’s own selective pathways to help fight cancer. FyMed has developed substantial preclinical evidence that its drug candidate, FY405B, could effectively kill colon cancer cells through in-vitro studies as well as in animal models of colon cancer.
“Our researchers have identified a specific protein that plays a critical role in processes that occur in the development of the malignant state,” according to the Company. “We are able to strategically target these pathways that are expressed in early colorectal cancer, when the tumor is attempting to escape immunologic surveillance”. This targeted drug thereby enables the anti-tumoral onslaught of immunomodulatory mechanisms and killing cancer cells at its core.
The Company plans to proceed with clinical trials of FY405B in the management of colon cancer. FyMed’s approach includes the strategic application of integrative clinical, pharmacogenomic, proteomic, and molecular phenotypic data with the decisive implementation of focused drug-centric models of companion diagnostics and prognostic driven modalities. Implementation of these approaches will enable the Company to sustain innovation, and lead to more effective and safer therapies in favor of product approval.
FyMed, Inc. is a pharmaceutical company with a growing portfolio of novel and improved pharmaceuticals developed and enhanced through targeted use of next-generation proteomic and genomic technologies in drug discovery and development. Leading innovations in precision medicine has enabled FyMed to effectively balance technological innovation with scientific discovery, creating tools that can productively capitalize on key market deficiencies.
Safe Harbor Statement
To the extent any statements made in this document contain information that is not historical, this news release contains “forward-looking statements” within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words “intends,” “plans,” “will,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described herein. These risks and uncertainties may include, without limitation, projected expansions, outcomes of our clinical trials, achievement of our business objectives, and the ability to obtain necessary regulatory approvals. FyMed undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.
Media Relations, FyMed, Inc.
3422 Old Capitol, Suite 1610
Wilmington, DE 19808